EMERYVILLE, Calif., July 21, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to...
Submission supported by comprehensive analytical data package and clinical Phase I pharmacokinetics bridging study Proposed Hyrimoz® HCF would help expand...
Portage now holds 100% ownership of iOx Therapeutics Ltd., buying out remainder of equity in exchange for PRTG stockWESTPORT, Conn.,...
Vaccine-induced mucosal IgA antibody responses persisted for up to 1 year and had a higher neutralizing activity compared with convalescent...
LAWRENCEVILLE, N.J., July 19, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage company focused on DNA-based immunotherapy and next-generation...
Michael H. Tardugno appointed Executive Chairman of the Board LAWRENCEVILLE, N.J., July 19, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN),...
SAN DIEGO, July 19, 2022 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science...
Bavarian Nordic to supply an additional 1.5 million doses of IMVANEX® vaccine to an undisclosed European countryDeliveries starting in the...
TORONTO, ONTARIO, July 15, 2022 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) ("Aeterna" or the "Company"), a...
Bavarian Nordic to supply an additional 2.5 million doses of JYNNEOS® vaccine, bringing deliveries in 2022 and 2023 to a...
As COVID-19 pandemic entered a new phase and changing workforce dynamics reshaped labor market, well-being improved in key well-being and...
- Horizon Platform Originates Record $192 Million of New Loans in Q2, Including $137 Million of New Loans for HRZN...
SOUTH SAN FRANCISCO, Calif., July 14, 2022 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that Dr. Sean Tucker,...
PDS0202 neutralized multiple strains of influenza and provided protection against infection in preclinical studiesFLORHAM PARK, N.J., July 14, 2022 (GLOBE...
New Facility in Austin Will Enable Increased Capacity for Internal Pipeline Assets While Accommodating Growing Interest in Partnered Projects Significantly...
Dupixent®(dupilumab) Phase 3 trial shows positive results in children 1 to 11 years of age with eosinophilic esophagitis First and...
• Phase 1 dose-escalation study started at clinical sites in the U.S. • Milestone demonstrates CureVac’s and GSK’s continued execution...
∙ The RNA Printer® is CureVac’s integrated and automated manufacturing solution for RNA vaccines and therapeutics ∙ CureVac RNA Printer...
Rolling submission to accelerate time to marketing authorization of CVnCoV in SwitzerlandReview process started with submission of first CVnCoV data...
Lessons from the most important tech adoption of our century: the COVID-19 vaccine By Cameron Turner, VP Data Science and...